Financial Report: Amylin 1Q11

Amylin 1Q11

1Q Revenues: $152.7 million (-12%)

1Q Loss: $37.3 million (loss of $38.2 million in 1Q10)

Comments: Byetta sales were $128.0 million (-15%). Collaborative profit sharing, which represents Lilly’s share of Byetta, was $59.9 million for the quarter, compared to $67.9 million for the same period in 2010. Symlin (pramlintide acetate) injection sales were $22.8 million (+1%). Revenues under collaborative agreements were flat at $1.9 million. During the quarter, the company notified its partner Lilly of its intent to draw a $165 million line of credit from Lilly.